Evaluation of transfection capacity into HEK cells of ferritin nanoparticles containing DNA vaccine

• Grant number: 19/25430-4
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: July 01, 2020
• End date: June 30, 2021
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Fabiana Testa Moura de Carvalho Vicentini
• Grantee: Gisele Mitsue Umino
• Host Institution: Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

DNA vaccines are plasmid constructs designed to express a coded protein antigen after in vivo administration and subsequent transfection of cells and tissues of interest (LIU, 2011). A gene-based vaccine offers molecular precision with the flexibility to induce immune responses against varied target antigens. However, one of the major challenges for effective use of DNA vaccines is choosing which approach to use to stimulate the immune system, in other words, using strategies to make DNA vaccines more immunogenic. In this context, the nanotechnology offers multiple platforms that can be used as adjuvants for this new generation of vaccines, enabling the ability to rationally design nanomaterials with specific surface size, shape, morphology and functionality. It is also possible to have the added benefit of choosing from various types of biodegradable and biocompatible materials (MAMO; POLAND, 2012). The present project is part of a project entitled: "Use of ferritin nanoparticles as a basis for the development of antitumor vaccine delivery systems" (FAPESP Process n° 2019/08891-8) under the coordination of Profa. Dr. Fabiana T.M.C. Vicentini. Considering the impact of the cellular uptake process for the efficacy of DNA vaccines, the evaluation of the developed systems behavior in the cell transfection process and the consequent formation of the protein of interest in HEK cells, the main objective of this project, becomes a crucial step for the understanding and selection of the best formulations to be employed in future immunogenicity studies.